Targets of emerging therapies for viral hepatitis B and C.

about

Hepatitis C protease and polymerase inhibitors in development Toll-like receptors signaling contributes to immunopathogenesis of HBV infection.Design, expression, and processing of epitomized hepatitis C virus-encoded CTL epitopes.

P2860

Q34085348-021E850E-2840-484B-95B2-CB6781439116 Q37970676-A45AE976-9286-4091-9155-A1723360A03D Q39926728-B58611B5-1806-49AC-AC60-149B05E47BF2

P2860

Targets of emerging therapies for viral hepatitis B and C.

Item

http://www.wikidata.org/entity/Q36653655

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Targets of emerging therapies for viral hepatitis B and C.

@ast

Targets of emerging therapies for viral hepatitis B and C.

@en

type

Item

label

Targets of emerging therapies for viral hepatitis B and C.

@ast

Targets of emerging therapies for viral hepatitis B and C.

@en

prefLabel

Targets of emerging therapies for viral hepatitis B and C.

@ast

Targets of emerging therapies for viral hepatitis B and C.

@en

P1476

Targets of emerging therapies for viral hepatitis B and C.

@en

P2093

Andreas Cerny

http://www.w3.org/2001/XMLSchema#string

Daniel Yerly

http://www.w3.org/2001/XMLSchema#string

Florian Bihl

http://www.w3.org/2001/XMLSchema#string

Loriana Di Giammarino

http://www.w3.org/2001/XMLSchema#string

P2860

Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity

Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex

Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes

Hepatitis C Virus Replicons Escape RNA Interference Induced by a Short Interfering RNA Directed against the NS5b Coding Region

Robust hepatitis C virus infection in vitro.

Inhibition of hepatitis C virus replication by antimonial compounds.

Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs

Broad Specificity of Virus-Specific CD4+ T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection

Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment To Prevent HCV Reinfection in Liver Transplant Patients

Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection.

P304

833-850

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728222.10.6.833

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17105371

http://www.w3.org/2001/XMLSchema#string

Targets of emerging therapies for viral hepatitis B and C.

about

P2860

P2860

Targets of emerging therapies for viral hepatitis B and C.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698